Our data demonstrate that CCND1 amplification is a stronger prognostic factor for outcomes following immunotherapy in melanoma than TMB and indicate that CCND1 amplification dramatically reduces patient survival regardless of the use of ICIs or TMB. Here, CCND1 is linked to melanoma.